메뉴 건너뛰기
New England Journal of Medicine
Volumn 372, Issue 7, 2015, Pages 683-684
The authors reply
Author keywords

[No Author keywords available]
Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; SCATTER FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;
EID: 84922722792     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1415359     Document Type: Letter
Times cited : (78)
References (5)
  • 1
    • 84911372597 scopus 로고    scopus 로고
    • Crizotinib in ROS1-rearranged non-small-cell lung cancer
    • Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71.
    • (2014) N Engl J Med , vol.371 , pp. 1963-1971
    • Shaw, A.T.1    S-Hi, O.2    Bang, Y.-J.3
  • 2
    • 74249112375 scopus 로고    scopus 로고
    • Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent nonsmall cell lung cancer after severe cutaneous toxicity
    • Lind JS, Postmus PE, Heideman DA, Thunnissen EB, Bekers O, Smit EF. Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent nonsmall cell lung cancer after severe cutaneous toxicity. J Thorac Oncol 2009;4:1585-6.
    • (2009) J Thorac Oncol , vol.4 , pp. 1585-1586
    • Lind, J.S.1    Postmus, P.E.2    Heideman, D.A.3    Thunnissen, E.B.4    Bekers, O.5    Smit, E.F.6
  • 3
    • 77954425045 scopus 로고    scopus 로고
    • Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
    • Yeo WL, Riely GJ, Yeap BY, et al. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010;5:1048-53.
    • (2010) J Thorac Oncol , vol.5 , pp. 1048-1053
    • Yeo, W.L.1    Riely, G.J.2    Yeap, B.Y.3
  • 4
    • 84871102869 scopus 로고    scopus 로고
    • Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash
    • Takashima N, Kimura T, Watanabe N, et al. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash. Onkologie 2012;35:747-52.
    • (2012) Onkologie , vol.35 , pp. 747-752
    • Takashima, N.1    Kimura, T.2    Watanabe, N.3
  • 5
    • 80054721163 scopus 로고    scopus 로고
    • Flushing oral oncology drugs down the toilet
    • Ratain MJ. Flushing oral oncology drugs down the toilet. J Clin Oncol 2011;29:3958-9.
    • (2011) J Clin Oncol , vol.29 , pp. 3958-3959
    • Ratain, M.J.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.